FDA Approves Hibsago: First Antisense Drug for Hepatitis B
FDA approves Hibsago (bepirovirsen) with antivirals for chronic hepatitis B; 19% kept viral control off treatment in trials, with a boxed warning.
GLP-1 Weight Loss Skin Changes: Beauty Giants Respond
GLP-1 weight loss skin changes are drawing L’Oréal, Natura and Galderma into testing products for facial volume loss and sagging skin.
Dr Reddy’s Zytorvi Approval: Bold Esophageal Cancer Win
Dr Reddy’s Zytorvi approval in India: toripalimab with chemotherapy for advanced esophageal cancer, 17.7 vs 12.9 months survival in JUPITER-06.
Nova Biomedical StatStrip Recall: Serious Patient-ID Risk
Nova Biomedical StatStrip recall: FDA lists the removal of Gen 2.0 hospital glucose meters over a patient-ID barcode risk. Gen 1.86 is not affected.
ALTB-268 Ulcerative Colitis Trial: Early Signal, Key Limits
ALTB-268 ulcerative colitis trial: AltruBio reports 23.1% week 12 remission on the higher dose in a small open-label Phase 2a. Still investigational.
Synergy Disc Clinical Study: Neck Pain Gains, Key Caveats
Synergy Disc clinical study: PERFORM reports lower neck pain and disability two years after cervical disc replacement. Open-label, no control group.
NeuroXT NEXT-Cue FDA Clearance: Bold AI Risk Tool
NeuroXT NEXT-Cue FDA clearance: AI helps clinicians assess five-year Alzheimer’s progression risk in mild cognitive impairment. Not a diagnosis.
Penumbra DVT FDA Clearance: Bold Clot-Removal Milestone
Penumbra DVT FDA clearance for Lightning CAVT: 98% near-complete clot removal in BOLT-DVT, per the company. What the data do and do not show.
Ebola Response Funding: Africa CDC Demands Key Answers
Ebola response funding: Africa CDC says $962M was disbursed but only about $200M accounted for. Officials seek records; no misuse is established.
Kenya Ebola Cases 2026: Ninth Case, Single Cluster
Kenya Ebola cases 2026 reach nine, all in one cluster per the ministry; 134 of 135 contacts traced. What is known and what is not.